Versacross Connect Laac Access Solution
Payments companies reported to CMS as associated with Versacross Connect Laac Access Solution. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Versacross Connect Laac Access Solution, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Versacross Connect Laac Access Solution
These are the largest totals companies reported as associated with Versacross Connect Laac Access Solution. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Lloyd | Atlanta, GA | Clinical Cardiac Electrophysiology | $1,322.97 |
| Benjamin Robalino Vidalon | Mcallen, TX | Cardiovascular Disease | $1,311.68 |
| Sartaj Hans | San Antonio, TX | Interventional Cardiology | $1,235.73 |
| Ian Laxina | Charleston, SC | Cardiovascular Disease | $1,196.74 |
| Mohammad Ostovaneh | Baltimore, MD | $1,168.71 | |
| Priyanka Bhattacharya | Charleston, SC | Cardiovascular Disease | $1,125.42 |
| Christopher Ellis | Nashville, TN | Cardiovascular Disease | $1,111.80 |
| Vivek Bhupathi | Fremont, CA | Internal Medicine | $1,090.72 |
| Abdel Rahman Omer | Grand Rapids, MI | Cardiovascular Disease | $1,065.52 |
| Eduardo Quintero | Philadelphia, PA | Internal Medicine | $1,050.56 |
Prescribed Versacross Connect Laac Access Solution?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.